Anne Lazareth

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells

Pierre Sesques, Jérémie Tordo, Emmanuelle Ferrant et al. · Clinical Nuclear Medicine · 2021 · 78 citations

Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

Estelle Bourbon, Delphine Maucort‐Boulch, Juliette Fontaine et al. · Blood Advances · 2021 · 61 citations · Full text

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases

Thorsten Braun, Stéphane de Botton, Anne‐Laure Taksin et al. · Leukemia Research · 2011 · 46 citations

Hematological Malignancy, Hematology, Isolated 20Q +3

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry

Benoît Ferment, Jérôme Lambert, Denis Caillot et al. · British Journal of Haematology · 2024 · 23 citations · Full text

Early Access Program, Immunodeficiencies, Immunology +20

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

Estelle Bourbon, Pierre Sesques, Morgane Gossez et al. · Blood Advances · 2022 · 21 citations · Full text

Car Therapy, Immunology, Pathology +18